Treatment for metastatic medullary thyroid cancer
Vandetanib (QTC prolongation)
Cabozantinib (Bowel perforation)
RET mutated –> Selpercatinib
Treatment for metastatic refractory differentiated thyroid cancer without targetable mutation
Sorafenib or Lenvatinib